Interferon gamma biosimilar - Recpharma

Drug Profile

Interferon gamma biosimilar - Recpharma

Alternative Names: IMMUNEX

Latest Information Update: 11 Jun 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Recpharma
  • Class Antineoplastics; Interferons; Lymphokines
  • Mechanism of Action Immunostimulants; Interferon gamma stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer; Chronic granulomatous disease; Osteopetrosis; Viral infections

Most Recent Events

  • 19 May 2015 Launched for Cancer in Iran (Parenteral) before May 2015
  • 19 May 2015 Launched for Chronic granulomatous disease in Iran (Parenteral) before May 2015
  • 19 May 2015 Launched for Osteopetrosis in Iran (Parenteral) before May 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top